Skip to main content
Top
Published in: Diabetes Therapy 8/2022

Open Access 29-06-2022 | Insulins | Original Research

Practical Guidance on Basal Insulin Initiation and Titration in Asia: A Delphi-Based Consensus

Authors: Siew Pheng Chan, Azizul Hasan Aamir, Yong Mong Bee, Chaicharn Deerochanawong, Elizabeth Paz-Pacheco, Fatma Tiu, Siew Hui Foo, Kevin E. K. Tan, Toan Q. Le, Made Ratna Saraswati, Pongamorn Bunnag, Roy Panusunan Sibarani, Syed Abbas Raza, Nam Quang Tran

Published in: Diabetes Therapy | Issue 8/2022

Login to get access

Abstract

The global health burden of diabetes is on the rise and has affected more than half a billion people worldwide, particularly in Southeast Asia, North Africa, Africa, and the Western Pacific, Middle East, and South and Central America regions of the International Diabetes Federation (IDF). Despite many new treatments being available for the management of diabetes, glycemic control remains suboptimal in Asia, compared to the rest of the world. Delay in timely insulin initiation and inadequate titration of insulin are regarded to be some of the important reasons for inadequate glycemic control. Additionally, Asian populations have a distinct phenotype, including a younger age of onset and higher glycemic excursions, suggestive of a lower beta-cell function, as compared to non-Asians. Although there are multiple local and international guidelines on insulin initiation and titration, some of these guidelines can be complex. There is an unmet need for guideline recommendations on basal insulin initiation and titration to be simplified and customized for the Asian population with type 2 diabetes mellitus (T2DM). A unified approach would increase adoption of basal insulin initiation by primary care and family medicine physicians, which in turn would help reduce the inertia to insulin initiation. With this background, a consensus-seeking meeting was conducted with 14 experts from seven Asian countries to delineate appropriate practices for insulin initiation and titration in the Asian context. The key objective was to propose a simple insulin titration algorithm, specific for the Asian population, to improve glycemic control and optimize therapeutic outcomes of people with T2DM on basal insulin. Following a detailed review of literature and current guidelines, and potential barriers to insulin initiation and titration, the experts proposed a simplified insulin titration algorithm based on both physician- and patient-led components. The consensus recommendations of the experts related to basal insulin initiation and titration have been summarized in this article, along with the proposed titration algorithm for optimizing glycemic control in the Asian population with T2DM.
Literature
2.
go back to reference Hussain A. Diabetes in Asia: special challenges and solutions. J Diabetol. 2018;9:69–72.CrossRef Hussain A. Diabetes in Asia: special challenges and solutions. J Diabetol. 2018;9:69–72.CrossRef
3.
go back to reference Chan JC, Yeung R, Luk A. The Asian diabetes phenotypes: challenges and opportunities. Diabetes Res Clin Pract. 2014;105(1):135–9.PubMedCrossRef Chan JC, Yeung R, Luk A. The Asian diabetes phenotypes: challenges and opportunities. Diabetes Res Clin Pract. 2014;105(1):135–9.PubMedCrossRef
4.
5.
go back to reference Chan JCN, Bunnag P, Chan SP, et al. Glycaemic responses in Asian and non-Asian people with type 2 diabetes initiating insulin glargine 100 units/mL: a patient-level pooled analysis of 16 randomised controlled trials. Diabetes Res Clin Pract. 2018;135:199–205.PubMedCrossRef Chan JCN, Bunnag P, Chan SP, et al. Glycaemic responses in Asian and non-Asian people with type 2 diabetes initiating insulin glargine 100 units/mL: a patient-level pooled analysis of 16 randomised controlled trials. Diabetes Res Clin Pract. 2018;135:199–205.PubMedCrossRef
6.
go back to reference Gujral UP, Pradeepa R, Weber MB, Narayan KM, Mohan V. Type 2 diabetes in South Asians: similarities and differences with white Caucasian and other populations. Ann N Y Acad Sci. 2013;1281(1):51–63.PubMedPubMedCentralCrossRef Gujral UP, Pradeepa R, Weber MB, Narayan KM, Mohan V. Type 2 diabetes in South Asians: similarities and differences with white Caucasian and other populations. Ann N Y Acad Sci. 2013;1281(1):51–63.PubMedPubMedCentralCrossRef
7.
8.
go back to reference Aschner P, Gagliardino JJ, Ilkova H, et al. Persistent poor glycaemic control in individuals with type 2 diabetes in developing countries: 12 years of real-world evidence of the International Diabetes Management Practices Study (IDMPS). Diabetologia. 2020;63(4):711–21.PubMedPubMedCentralCrossRef Aschner P, Gagliardino JJ, Ilkova H, et al. Persistent poor glycaemic control in individuals with type 2 diabetes in developing countries: 12 years of real-world evidence of the International Diabetes Management Practices Study (IDMPS). Diabetologia. 2020;63(4):711–21.PubMedPubMedCentralCrossRef
9.
go back to reference Chan JCN, Gagliardino JJ, Ilkova H, et al. One in seven insulin-treated patients in developing countries reported poor persistence with insulin therapy: real world evidence from the cross-sectional International Diabetes Management Practices Study (IDMPS). Adv Ther. 2021;38(6):3281–98.PubMedPubMedCentralCrossRef Chan JCN, Gagliardino JJ, Ilkova H, et al. One in seven insulin-treated patients in developing countries reported poor persistence with insulin therapy: real world evidence from the cross-sectional International Diabetes Management Practices Study (IDMPS). Adv Ther. 2021;38(6):3281–98.PubMedPubMedCentralCrossRef
11.
go back to reference Suastika K. The challenges of metabolic disorders in Indonesia: focus on metabolic syndrome, prediabetes, and diabetes. Med J Indones. 2020;29(4):350–3.CrossRef Suastika K. The challenges of metabolic disorders in Indonesia: focus on metabolic syndrome, prediabetes, and diabetes. Med J Indones. 2020;29(4):350–3.CrossRef
12.
go back to reference Deerochanawong C, Leelawattana R, Kosachunhanun N, Tantiwong P. Basal insulin dose titration for glycemic control in patients with type 2 diabetes mellitus in Thailand: results of the REWARDS real-world Study. Clin Med Insights Endocrinol Diabetes. 2020;13:1179551420935930.PubMedPubMedCentralCrossRef Deerochanawong C, Leelawattana R, Kosachunhanun N, Tantiwong P. Basal insulin dose titration for glycemic control in patients with type 2 diabetes mellitus in Thailand: results of the REWARDS real-world Study. Clin Med Insights Endocrinol Diabetes. 2020;13:1179551420935930.PubMedPubMedCentralCrossRef
13.
go back to reference Jabbar A, Mohamed WMIBW, Ozaki R, et al. Patterns and trends in insulin initiation and intensification among patients with type 2 diabetes mellitus in the Western Pacific region. Curr Med Res Opin. 2018;34(9):1653–62.PubMedCrossRef Jabbar A, Mohamed WMIBW, Ozaki R, et al. Patterns and trends in insulin initiation and intensification among patients with type 2 diabetes mellitus in the Western Pacific region. Curr Med Res Opin. 2018;34(9):1653–62.PubMedCrossRef
14.
go back to reference Soewondo P, Soegondo S, Suastika K, Pranoto A, Soeatmadji DW, Tjokroprawiro A. The DiabCare Asia 2008 study: outcomes on control and complications of type 2 diabetic patients in Indonesia. Med J Indones. 2010;19(4):235–44.CrossRef Soewondo P, Soegondo S, Suastika K, Pranoto A, Soeatmadji DW, Tjokroprawiro A. The DiabCare Asia 2008 study: outcomes on control and complications of type 2 diabetic patients in Indonesia. Med J Indones. 2010;19(4):235–44.CrossRef
15.
go back to reference Chan WB, Chen JF, Goh SY, et al. Challenges and unmet needs in basal insulin therapy: lessons from the Asian experience. Diabetes Metab Syndr Obes. 2017;10:521–32.PubMedPubMedCentralCrossRef Chan WB, Chen JF, Goh SY, et al. Challenges and unmet needs in basal insulin therapy: lessons from the Asian experience. Diabetes Metab Syndr Obes. 2017;10:521–32.PubMedPubMedCentralCrossRef
16.
go back to reference Jain SM, Seshadri K, Unnikrishnan AG, et al. Best practices and tools for titrating basal insulins: expert opinion from an Indian panel via the modified Delphi consensus method. Diabetes Ther. 2020;11(3):621–32.PubMedPubMedCentralCrossRef Jain SM, Seshadri K, Unnikrishnan AG, et al. Best practices and tools for titrating basal insulins: expert opinion from an Indian panel via the modified Delphi consensus method. Diabetes Ther. 2020;11(3):621–32.PubMedPubMedCentralCrossRef
18.
go back to reference Deerochanawong C, Bajpai S, Dwipayana IMP, et al. Optimizing glycemic control through titration of insulin glargine 100 U/mL. A review of current and future approaches with a focus on Asian populations. Diabetes Ther. 2017;8:1197–214.PubMedPubMedCentralCrossRef Deerochanawong C, Bajpai S, Dwipayana IMP, et al. Optimizing glycemic control through titration of insulin glargine 100 U/mL. A review of current and future approaches with a focus on Asian populations. Diabetes Ther. 2017;8:1197–214.PubMedPubMedCentralCrossRef
19.
go back to reference Soewondo P. Current practice in the management of type 2 diabetes in Indonesia: results from the International Diabetes Management Practices Study (IDMPS). J Indon Med Assoc. 2011;61(12):474–81. Soewondo P. Current practice in the management of type 2 diabetes in Indonesia: results from the International Diabetes Management Practices Study (IDMPS). J Indon Med Assoc. 2011;61(12):474–81.
21.
go back to reference American Diabetes Association. Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S1–264.CrossRef American Diabetes Association. Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S1–264.CrossRef
22.
go back to reference Bergenstal RM, Gavin JR, Global Consensus Conference on Glucose Monitoring Panel. The role of self-monitoring of blood glucose in the care of people with diabetes: report of a global consensus conference. Am J Med. 2005;118(Suppl 9A):1S-6S.PubMedCrossRef Bergenstal RM, Gavin JR, Global Consensus Conference on Glucose Monitoring Panel. The role of self-monitoring of blood glucose in the care of people with diabetes: report of a global consensus conference. Am J Med. 2005;118(Suppl 9A):1S-6S.PubMedCrossRef
23.
go back to reference Erbach M, Freckmann G, Hinzmann R, et al. Interferences and limitations in blood glucose self-testing: an overview of the current knowledge. J Diabetes Sci Technol. 2016;10(5):1161–8.PubMedPubMedCentralCrossRef Erbach M, Freckmann G, Hinzmann R, et al. Interferences and limitations in blood glucose self-testing: an overview of the current knowledge. J Diabetes Sci Technol. 2016;10(5):1161–8.PubMedPubMedCentralCrossRef
24.
go back to reference Ong WM, Chua SS, Ng CJ. Barriers and facilitators to self-monitoring of blood glucose in people with type 2 diabetes using insulin: a qualitative study. Patient Prefer Adher. 2014;8:237–46. Ong WM, Chua SS, Ng CJ. Barriers and facilitators to self-monitoring of blood glucose in people with type 2 diabetes using insulin: a qualitative study. Patient Prefer Adher. 2014;8:237–46.
25.
go back to reference Chowdhury S, Ji L, Suwanwalaikorn S, Yu NC, Tan EK. Practical approaches for self-monitoring of blood glucose: an Asia-Pacific perspective. Curr Med Res Opin. 2015;31(3):461–76.PubMedCrossRef Chowdhury S, Ji L, Suwanwalaikorn S, Yu NC, Tan EK. Practical approaches for self-monitoring of blood glucose: an Asia-Pacific perspective. Curr Med Res Opin. 2015;31(3):461–76.PubMedCrossRef
27.
go back to reference Hancu N, Janez A, Lalic N, et al. Expert opinion: a call for basal insulin titration in patients with type 2 diabetes in daily practice: southeast European perspective. Diabetes Ther. 2021;12(5):1575–89.PubMedPubMedCentralCrossRef Hancu N, Janez A, Lalic N, et al. Expert opinion: a call for basal insulin titration in patients with type 2 diabetes in daily practice: southeast European perspective. Diabetes Ther. 2021;12(5):1575–89.PubMedPubMedCentralCrossRef
28.
29.
go back to reference Wong S, Lee J, Ko Y, Chong MF, Lam CK, Tang WE. Perceptions of insulin therapy amongst Asian patients with diabetes in Singapore. Diabet Med. 2011;28(2):206–11.PubMedCrossRef Wong S, Lee J, Ko Y, Chong MF, Lam CK, Tang WE. Perceptions of insulin therapy amongst Asian patients with diabetes in Singapore. Diabet Med. 2011;28(2):206–11.PubMedCrossRef
31.
go back to reference Mehta R, Goldenberg R, Katselnik D, Kuritzky L. Practical guidance on the initiation, titration, and switching of basal insulins: a narrative review for primary care. Ann Med. 2021;53(1):998–1009.PubMedPubMedCentralCrossRef Mehta R, Goldenberg R, Katselnik D, Kuritzky L. Practical guidance on the initiation, titration, and switching of basal insulins: a narrative review for primary care. Ann Med. 2021;53(1):998–1009.PubMedPubMedCentralCrossRef
32.
go back to reference Kalra S, Gupta Y. Clinical use of insulin degludec: practical experience and pragmatic suggestions. North Am J Med Sci. 2015;7:81–5.CrossRef Kalra S, Gupta Y. Clinical use of insulin degludec: practical experience and pragmatic suggestions. North Am J Med Sci. 2015;7:81–5.CrossRef
33.
go back to reference Baser O, Tangirala K, Wei W, Xie L. Real-world outcomes of initiating insulin glargine-based treatment versus premixed analog insulins among US patients with type 2 diabetes failing oral antidiabetic drugs. Clinicoecon Outcomes Res. 2013;5:497–505.PubMedPubMedCentralCrossRef Baser O, Tangirala K, Wei W, Xie L. Real-world outcomes of initiating insulin glargine-based treatment versus premixed analog insulins among US patients with type 2 diabetes failing oral antidiabetic drugs. Clinicoecon Outcomes Res. 2013;5:497–505.PubMedPubMedCentralCrossRef
34.
go back to reference Zhang Y, Xie YJ, Meng DD, Zhang HH, Chen H, Liu E. Clinical study of treatment switching from premixed insulin to basal insulin combined with oral hypoglycemic drugs in patients with type 2 diabetes. Diabetol Metab Syndr. 2014;6(1):37.PubMedPubMedCentralCrossRef Zhang Y, Xie YJ, Meng DD, Zhang HH, Chen H, Liu E. Clinical study of treatment switching from premixed insulin to basal insulin combined with oral hypoglycemic drugs in patients with type 2 diabetes. Diabetol Metab Syndr. 2014;6(1):37.PubMedPubMedCentralCrossRef
35.
go back to reference Ji L, Zhang P, Zhu D, et al. Observational Registry of Basal Insulin Treatment (ORBIT) in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic drugs: real-life use of basal insulin in China. Diabetes Obes Metab. 2017;19(6):822–30.PubMedCrossRef Ji L, Zhang P, Zhu D, et al. Observational Registry of Basal Insulin Treatment (ORBIT) in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic drugs: real-life use of basal insulin in China. Diabetes Obes Metab. 2017;19(6):822–30.PubMedCrossRef
36.
go back to reference Cheng AYY, Wong J, Freemantle N, Acharya SH, Ekinci E. The safety and efficacy of second-generation basal insulin analogues in adults with type 2 diabetes at risk of hypoglycemia and use in other special populations: a narrative review. Diabetes Ther. 2020;11(11):2555–93.PubMedPubMedCentralCrossRef Cheng AYY, Wong J, Freemantle N, Acharya SH, Ekinci E. The safety and efficacy of second-generation basal insulin analogues in adults with type 2 diabetes at risk of hypoglycemia and use in other special populations: a narrative review. Diabetes Ther. 2020;11(11):2555–93.PubMedPubMedCentralCrossRef
37.
go back to reference Mauricio D, Hramiak I. Second-generation insulin analogues-a review of recent real-world data and forthcoming head-to-head comparisons. Eur Endocrinol. 2018;14(Suppl1):2–9.PubMedPubMedCentralCrossRef Mauricio D, Hramiak I. Second-generation insulin analogues-a review of recent real-world data and forthcoming head-to-head comparisons. Eur Endocrinol. 2018;14(Suppl1):2–9.PubMedPubMedCentralCrossRef
39.
go back to reference Shera AS, Basit A, Prompt Team. Pakistan’s recommendations for optimal management of diabetes from primary to tertiary care level (PROMPT). Pak J Med Sci. 2017;33(5):1279–83.PubMedPubMedCentralCrossRef Shera AS, Basit A, Prompt Team. Pakistan’s recommendations for optimal management of diabetes from primary to tertiary care level (PROMPT). Pak J Med Sci. 2017;33(5):1279–83.PubMedPubMedCentralCrossRef
40.
46.
go back to reference Chawla R, Makkar BM, Aggarwal S, et al. RSSDI consensus recommendations on insulin therapy in the management of diabetes. Int J Diabetes Dev Ctries. 2019;39(2):1–52. Chawla R, Makkar BM, Aggarwal S, et al. RSSDI consensus recommendations on insulin therapy in the management of diabetes. Int J Diabetes Dev Ctries. 2019;39(2):1–52.
47.
go back to reference Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. Endocr Pract. 2020;26(1):107–39.PubMedCrossRef Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. Endocr Pract. 2020;26(1):107–39.PubMedCrossRef
48.
go back to reference Ji L, Wan H, Wen B, et al. Higher versus standard starting dose of insulin glargine 100 U/mL in overweight or obese Chinese patients with type 2 diabetes: results of a multicentre, open-label, randomized controlled trial (BEYOND VII). Diabetes Obes Metab. 2020;22(5):838–46.PubMedPubMedCentralCrossRef Ji L, Wan H, Wen B, et al. Higher versus standard starting dose of insulin glargine 100 U/mL in overweight or obese Chinese patients with type 2 diabetes: results of a multicentre, open-label, randomized controlled trial (BEYOND VII). Diabetes Obes Metab. 2020;22(5):838–46.PubMedPubMedCentralCrossRef
49.
go back to reference Tsai ST, Chan J, Bunnag P, et al. Comparison of glycemic control in Asian and non-Asian T2D patients initiating insulin glargine 100 U/mL as add-on therapy to OADs. Diabetes Res Clin Pract. 2016;120:S114–5.CrossRef Tsai ST, Chan J, Bunnag P, et al. Comparison of glycemic control in Asian and non-Asian T2D patients initiating insulin glargine 100 U/mL as add-on therapy to OADs. Diabetes Res Clin Pract. 2016;120:S114–5.CrossRef
50.
go back to reference Rosenstock J, Aronson R, Grunberger G, et al. Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the LixiLan-O randomized trial. Diabetes Care. 2016;39(11):2026–35.PubMedCrossRef Rosenstock J, Aronson R, Grunberger G, et al. Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the LixiLan-O randomized trial. Diabetes Care. 2016;39(11):2026–35.PubMedCrossRef
51.
go back to reference Gomez-Peralta F, Al-Ozairi E, Jude EB, Li X, Rosenstock J. Titratable fixed-ratio combination of basal insulin plus a glucagon-like peptide-1 receptor agonist: a novel, simplified alternative to premix insulin for type 2 diabetes. Diabetes Obes Metab. 2021;23(7):1445–52.PubMedPubMedCentralCrossRef Gomez-Peralta F, Al-Ozairi E, Jude EB, Li X, Rosenstock J. Titratable fixed-ratio combination of basal insulin plus a glucagon-like peptide-1 receptor agonist: a novel, simplified alternative to premix insulin for type 2 diabetes. Diabetes Obes Metab. 2021;23(7):1445–52.PubMedPubMedCentralCrossRef
52.
go back to reference Skolnik N, Hinnen D, Kiriakov Y, Magwire ML, White JR Jr. Initiating titratable fixed-ratio combinations of basal insulin analogs and glucagon-like peptide-1 receptor agonists: what you need to know. Clin Diabetes. 2018;36(2):174–82.PubMedPubMedCentralCrossRef Skolnik N, Hinnen D, Kiriakov Y, Magwire ML, White JR Jr. Initiating titratable fixed-ratio combinations of basal insulin analogs and glucagon-like peptide-1 receptor agonists: what you need to know. Clin Diabetes. 2018;36(2):174–82.PubMedPubMedCentralCrossRef
53.
go back to reference Haluzík M, Flekač M, Lengyel C, et al. Expert opinion on the therapeutic use of the fixed-ratio combination of insulin glargine 100 U/mL and lixisenatide: a central/eastern European perspective. Diabetes Ther. 2020;11(4):1029–43.PubMedPubMedCentralCrossRef Haluzík M, Flekač M, Lengyel C, et al. Expert opinion on the therapeutic use of the fixed-ratio combination of insulin glargine 100 U/mL and lixisenatide: a central/eastern European perspective. Diabetes Ther. 2020;11(4):1029–43.PubMedPubMedCentralCrossRef
54.
go back to reference Gallwitz B. Clinical Use of DPP-4 inhibitors. Front Endocrinol (Lausanne). 2019;10:389.CrossRef Gallwitz B. Clinical Use of DPP-4 inhibitors. Front Endocrinol (Lausanne). 2019;10:389.CrossRef
55.
go back to reference Scheen AJ. Combined thiazolidinedione-insulin therapy: should we be concerned about safety? Drug Saf. 2004;27(12):841–56.PubMedCrossRef Scheen AJ. Combined thiazolidinedione-insulin therapy: should we be concerned about safety? Drug Saf. 2004;27(12):841–56.PubMedCrossRef
56.
go back to reference Tsai ST, Pathan F, Ji L, et al. First insulinization with basal insulin in patients with type 2 diabetes in a real-world setting in Asia. J Diabetes. 2011;3(3):208–16.PubMedCrossRef Tsai ST, Pathan F, Ji L, et al. First insulinization with basal insulin in patients with type 2 diabetes in a real-world setting in Asia. J Diabetes. 2011;3(3):208–16.PubMedCrossRef
57.
go back to reference Ji L, Tsai ST, Lin J, Bhambani S. National variations in comorbidities, glycosylated hemoglobin reduction, and insulin dosage in Asian patients with type 2 diabetes: the FINE-Asia registry. Diabetes Ther. 2015;6(4):519–30.PubMedPubMedCentralCrossRef Ji L, Tsai ST, Lin J, Bhambani S. National variations in comorbidities, glycosylated hemoglobin reduction, and insulin dosage in Asian patients with type 2 diabetes: the FINE-Asia registry. Diabetes Ther. 2015;6(4):519–30.PubMedPubMedCentralCrossRef
58.
go back to reference Home P, Naggar NE, Khamseh M, et al. An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: the A1chieve study. Diabetes Res Clin Pract. 2011;94(3):352–63.PubMedCrossRef Home P, Naggar NE, Khamseh M, et al. An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: the A1chieve study. Diabetes Res Clin Pract. 2011;94(3):352–63.PubMedCrossRef
59.
go back to reference Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R, ATLANTUS Study Group. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care. 2005;28(6):1282–8.PubMedCrossRef Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R, ATLANTUS Study Group. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care. 2005;28(6):1282–8.PubMedCrossRef
60.
go back to reference Yki-Järvinen H, Kauppinen-Makelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia. 2006;49(3):442–51.PubMedCrossRef Yki-Järvinen H, Kauppinen-Makelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia. 2006;49(3):442–51.PubMedCrossRef
61.
go back to reference Yki-Järvinen H, Juurinen L, Alvarsson M, et al. INITIATE (Initiate Insulin by Aggressive Titration and Education): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care. 2007;30(6):1364–9.PubMed Yki-Järvinen H, Juurinen L, Alvarsson M, et al. INITIATE (Initiate Insulin by Aggressive Titration and Education): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care. 2007;30(6):1364–9.PubMed
62.
go back to reference Meneghini L, Koenen C, Weng W, Selam JL. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes–results of the randomized, controlled PREDICTIVE 303 study. Diabetes Obes Metab. 2007;9(6):902–13.PubMedCrossRef Meneghini L, Koenen C, Weng W, Selam JL. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes–results of the randomized, controlled PREDICTIVE 303 study. Diabetes Obes Metab. 2007;9(6):902–13.PubMedCrossRef
63.
go back to reference Cheng AYY, Patel DK, Reid TS, Wyne K. Differentiating basal insulin preparations: understanding how they work explains why they are different. Adv Ther. 2019;36(5):1018–30.PubMedPubMedCentralCrossRef Cheng AYY, Patel DK, Reid TS, Wyne K. Differentiating basal insulin preparations: understanding how they work explains why they are different. Adv Ther. 2019;36(5):1018–30.PubMedPubMedCentralCrossRef
64.
go back to reference Philis-Tsimikas A, Brod M, Niemeyer M, Ocampo Francisco AM, Rothman J. Insulin degludec oncedaily in type 2 diabetes: simple or step-wise titration (BEGIN: once simple use). Adv Ther. 2013;30:607–22.PubMedPubMedCentralCrossRef Philis-Tsimikas A, Brod M, Niemeyer M, Ocampo Francisco AM, Rothman J. Insulin degludec oncedaily in type 2 diabetes: simple or step-wise titration (BEGIN: once simple use). Adv Ther. 2013;30:607–22.PubMedPubMedCentralCrossRef
65.
go back to reference Yale JF, Berard L, Groleau M, Javadi P, Stewart J, Harris SB. TITRATION: a randomized study to assess 2 treatment algorithms with new insulin glargine 300 units/mL. Can J Diabetes. 2017;41(5):478–84.PubMedCrossRef Yale JF, Berard L, Groleau M, Javadi P, Stewart J, Harris SB. TITRATION: a randomized study to assess 2 treatment algorithms with new insulin glargine 300 units/mL. Can J Diabetes. 2017;41(5):478–84.PubMedCrossRef
66.
go back to reference Rosenstock J, Cheng A, Ritzel R, et al. More similarities than differences testing insulin glargine 300 Units/mL versus insulin degludec 100 units/ml in insulin-naive type 2 diabetes: the randomized head-to-head BRIGHT trial. Diabetes Care. 2018;41(10):2147–54.PubMedCrossRef Rosenstock J, Cheng A, Ritzel R, et al. More similarities than differences testing insulin glargine 300 Units/mL versus insulin degludec 100 units/ml in insulin-naive type 2 diabetes: the randomized head-to-head BRIGHT trial. Diabetes Care. 2018;41(10):2147–54.PubMedCrossRef
67.
go back to reference Cheng A, Harris S, Giorgino F, et al. Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: a subanalysis of the BRIGHT study. Diabetes Obes Metab. 2020;22(3):346–54.PubMedCrossRef Cheng A, Harris S, Giorgino F, et al. Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: a subanalysis of the BRIGHT study. Diabetes Obes Metab. 2020;22(3):346–54.PubMedCrossRef
68.
go back to reference Garg SK, Admane K, Freemantle N, et al. Patient-led versus physician-led titration of insulin glargine in patients with uncontrolled type 2 diabetes: a randomized multinational ATLAS study. Endocr Pract. 2015;21(2):143–57.PubMedCrossRef Garg SK, Admane K, Freemantle N, et al. Patient-led versus physician-led titration of insulin glargine in patients with uncontrolled type 2 diabetes: a randomized multinational ATLAS study. Endocr Pract. 2015;21(2):143–57.PubMedCrossRef
69.
70.
go back to reference Widyahening IS, van der Graaf Y, Soewondo P, Glasziou P, van der Heijden GJM. Awareness, agreement, adoption and adherence to type 2 diabetes mellitus guidelines: a survey of Indonesian primary care physicians. BMC Fam Pract. 2014;15:72.PubMedPubMedCentralCrossRef Widyahening IS, van der Graaf Y, Soewondo P, Glasziou P, van der Heijden GJM. Awareness, agreement, adoption and adherence to type 2 diabetes mellitus guidelines: a survey of Indonesian primary care physicians. BMC Fam Pract. 2014;15:72.PubMedPubMedCentralCrossRef
71.
go back to reference Rudijanto A, Saraswati MR, Yunir E, Kumala P, Puteri HH, Mandang VV. Indonesia cohort of IO HAT study to evaluate diabetes management, control, and complications in retrospective and prospective periods among insulin-treated patients with type 1 and type 2 diabetes. Acta Med Indones. 2018;50(1):26–37.PubMed Rudijanto A, Saraswati MR, Yunir E, Kumala P, Puteri HH, Mandang VV. Indonesia cohort of IO HAT study to evaluate diabetes management, control, and complications in retrospective and prospective periods among insulin-treated patients with type 1 and type 2 diabetes. Acta Med Indones. 2018;50(1):26–37.PubMed
72.
go back to reference Yunir E, Soewondo P, Soelistijo SA, Rudijanto A. Knowledge and behavior changes in clinician after training of partnership for Diabetes Control in Indonesia. Diabetes Metab Syndr. 2021;15(3):719–24.PubMedCrossRef Yunir E, Soewondo P, Soelistijo SA, Rudijanto A. Knowledge and behavior changes in clinician after training of partnership for Diabetes Control in Indonesia. Diabetes Metab Syndr. 2021;15(3):719–24.PubMedCrossRef
Metadata
Title
Practical Guidance on Basal Insulin Initiation and Titration in Asia: A Delphi-Based Consensus
Authors
Siew Pheng Chan
Azizul Hasan Aamir
Yong Mong Bee
Chaicharn Deerochanawong
Elizabeth Paz-Pacheco
Fatma Tiu
Siew Hui Foo
Kevin E. K. Tan
Toan Q. Le
Made Ratna Saraswati
Pongamorn Bunnag
Roy Panusunan Sibarani
Syed Abbas Raza
Nam Quang Tran
Publication date
29-06-2022
Publisher
Springer Healthcare
Published in
Diabetes Therapy / Issue 8/2022
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-022-01286-0

Other articles of this Issue 8/2022

Diabetes Therapy 8/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine